Hansa Biopharma AB (HNSA) Stock Statistics & Valuation Metrics

Hansa Biopharma AB has a market cap or net worth of kr1.48B. The enterprise value is kr3.33B.

Hansa Biopharma AB has 67.81M shares outstanding. The number of shares has decreased by -2.65% in one year.

Hansa Biopharma AB’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Hansa Biopharma AB is -3.05. Hansa Biopharma AB’s PEG ratio is 0.16.

In the last 12 months, Hansa Biopharma AB had revenue of kr171.32M and earned -kr806.74M in profits. Earnings per share was -kr13.06.

In the last 12 months, operating cash flow was -kr733.92M and capital expenditures -kr116.00K, giving a free cash flow of -kr734.04M billion.

Hansa Biopharma AB pays an annual dividend of , resulting in a dividend yield of

Hansa Biopharma AB upcoming earnings date is Apr 17, 2025, Before Open.

Hansa Biopharma AB as a current ratio of 2.29, with Debt / Equity ratio of -1.83

In the past 12 months, Hansa Biopharma AB has paid kr3.01M in taxes.

Hansa Biopharma AB EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Hansa Biopharma AB has kr405.28M in cash and marketable securities with kr1.08B in debt, giving a net cash position of kr673.73M billion.

Gross margin is 51.23%, with operating margin of -370.28%, and net profit margin of -470.91%.

The average price target for Hansa Biopharma AB is kr143.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy